Aligos Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Aligos Therapeutics, Inc. (ALGS) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent of -74.22% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-05
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2025 was -74.22%.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2024 was -17.04%, a 119.66% decline from fiscal 2023.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2023 was 86.68%.
- Aligos Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2022 was -26.32%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month |
|---|---|
| 2025-12-31 | -74.22% 10-K · filed 2026-03-05 |
| 2024-12-31 | -17.04% 10-K · filed 2026-03-05 |
| 2023-12-31 | 86.68% 10-K · filed 2025-03-10 |
| 2022-12-31 | -26.32% 10-K · filed 2024-03-12 |
| 2021-12-31 | -27.42% 10-K · filed 2023-03-09 |
| 2020-12-31 | -27.24% 10-K · filed 2022-03-10 |
| 2019-12-31 | -29.71% 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |